

Global and United States Tourette Syndrome Drug In-Depth Research Report 2017-2022

<https://marketpublishers.com/r/G2A5569F848EN.html>

Date: December 2017

Pages: 105

Price: US\$ 3,190.00 (Single User License)

ID: G2A5569F848EN

Abstracts

The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2017 to 2022.

This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Tourette Syndrome Drug industry.

Major Companies

Abide Therapeutics Inc
Catalyst Pharmaceuticals Inc
Neurocrine Biosciences Inc
Psyadon Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Synchronuron Inc
Teva Pharmaceutical Industries Ltd
Therapix Biosciences Ltd

Key Regions

North America
United States
California
Texas
New York

Others

Canada

Latin America

Mexico

Brazil

Argentina

Others

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Netherland

Others

Asia & Pacific

China

Japan

India

Korea

Australia

Southeast Asia

Indonesia

Thailand

Philippines

Vietnam

Singapore

Malaysia

Others

Africa & Middle East

South Africa

Egypt

Turkey

Saudi Arabia

Iran

Others

Main types of products

Tourette Syndrome Drug Market, byD-5213
Tourette Syndrome Drug Market, byP-115
Tourette Syndrome Drug Market, bytetrabenazine ER
Tourette Syndrome Drug Market, byopipam Hydrochloride
Tourette Syndrome Drug Market, byhers

Tourette Syndrome Drug Market, by Key Consumers

Research Center
Hospital
Clinic
Others

Contents

CHAPTER ONE GLOBAL TOURETTE SYNDROME DRUG MARKET OVERVIEW

1.1 Global Tourette Syndrome Drug Market Sales Volume Revenue and Price 2012-2017

1.2 Tourette Syndrome Drug, by -5213 2012-2017

1.2.1 Global Tourette Syndrome Drug Sales Market Share by -5213 2012-2017

1.2.2 Global Tourette Syndrome Drug Revenue Market Share by -5213 2012-2017

1.2.3 Global Tourette Syndrome Drug Price by -5213 2012-2017

1.2.4

1.2.5

1.3 Tourette Syndrome Drug, by -115 2012-2017

1.3.1 Global Tourette Syndrome Drug Sales Market Share by -115 2012-2017

1.3.2 Global Tourette Syndrome Drug Revenue Market Share by -115 2012-2017

1.3.3 Global Tourette Syndrome Drug Price by -115 2012-2017

1.3.4

1.3.5

1.4 Tourette Syndrome Drug, by etrabenazine ER 2012-2017

1.4.1 Global Tourette Syndrome Drug Sales Market Share by etrabenazine ER 2012-2017

1.4.2 Global Tourette Syndrome Drug Revenue Market Share by etrabenazine ER 2012-2017

1.4.3 Global Tourette Syndrome Drug Price by etrabenazine ER 2012-2017

1.4.4

1.4.5

1.5 Tourette Syndrome Drug, by pipam Hydrochloride 2012-2017

1.5.1 Global Tourette Syndrome Drug Sales Market Share by pipam Hydrochloride 2012-2017

1.5.2 Global Tourette Syndrome Drug Revenue Market Share by pipam Hydrochloride 2012-2017

1.5.3 Global Tourette Syndrome Drug Price by pipam Hydrochloride 2012-2017

1.5.4

1.5.5

1.6 Tourette Syndrome Drug, by ers 2012-2017

1.6.1 Global Tourette Syndrome Drug Sales Market Share by ers 2012-2017

1.6.2 Global Tourette Syndrome Drug Revenue Market Share by ers 2012-2017

1.6.3 Global Tourette Syndrome Drug Price by ers 2012-2017

1.6.4

1.6.5

CHAPTER TWO UNITED STATES TOURETTE SYNDROME DRUG MARKET OVERVIEW

2.1 United States Tourette Syndrome Drug Market Sales Volume Revenue and Price 2012-2017

2.2 Tourette Syndrome Drug, by -5213 2012-2017

2.2.1 United States Tourette Syndrome Drug Sales Market Share by -5213 2012-2017

2.2.2 United States Tourette Syndrome Drug Revenue Market Share by -5213

2012-2017

2.2.3 United States Tourette Syndrome Drug Price by -5213 2012-2017

2.2.4

2.2.5

2.3 Tourette Syndrome Drug, by -115 2012-2017

2.3.1 United States Tourette Syndrome Drug Sales Market Share by -115 2012-2017

2.3.2 United States Tourette Syndrome Drug Revenue Market Share by -115

2012-2017

2.3.3 United States Tourette Syndrome Drug Price by -115 2012-2017

2.3.4

2.3.5

2.4 Tourette Syndrome Drug, by etrabenazine ER 2012-2017

2.4.1 United States Tourette Syndrome Drug Sales Market Share by etrabenazine ER 2012-2017

2.4.2 United States Tourette Syndrome Drug Revenue Market Share by etrabenazine ER 2012-2017

2.4.3 United States Tourette Syndrome Drug Price by etrabenazine ER 2012-2017

2.4.4

2.4.5

2.5 Tourette Syndrome Drug, by pipam Hydrochloride 2012-2017

2.5.1 United States Tourette Syndrome Drug Sales Market Share by pipam Hydrochloride 2012-2017

2.5.2 United States Tourette Syndrome Drug Revenue Market Share by pipam Hydrochloride 2012-2017

2.5.3 United States Tourette Syndrome Drug Price by pipam Hydrochloride 2012-2017

2.5.4

2.5.5

2.6 Tourette Syndrome Drug, by ers 2012-2017

2.6.1 United States Tourette Syndrome Drug Sales Market Share by ers 2012-2017

- 2.6.2 United States Tourette Syndrome Drug Revenue Market Share by ers 2012-2017
- 2.6.3 United States Tourette Syndrome Drug Price by ers 2012-2017
- 2.6.4
- 2.6.5

CHAPTER THREE TOURETTE SYNDROME DRUG BY REGIONS 2012-2017

- 3.1 Global Tourette Syndrome Drug Sales Market Share by Regions 2012-2017
- 3.2 Global Tourette Syndrome Drug Revenue Market Share by Regions 2012-2017
- 3.3 Global Tourette Syndrome Drug Price by Regions 2012-2017
- 3.4 North America
 - 3.4.1 United States
 - 3.4.1.1 California
 - 3.4.1.2 Texas
 - 3.4.1.3 New York
 - 3.4.1.4 Others in United States
 - 3.4.2 Canada
- 3.5 Latin America
 - 3.5.1 Mexico
 - 3.5.2 Brazil
 - 3.5.3 Argentina
 - 3.5.4 Others in Latin America
- 3.6 Europe
 - 3.6.1 Germany
 - 3.6.2 United Kingdom
 - 3.6.3 France
 - 3.6.4 Italy
 - 3.6.5 Spain
 - 3.6.6 Russia
 - 3.6.7 Netherland
 - 3.6.8 Others in Europe
- 3.7 Asia & Pacific
 - 3.7.1 China
 - 3.7.2 Japan
 - 3.7.3 India
 - 3.7.4 Korea
 - 3.7.5 Australia
 - 3.7.6 Southeast Asia
 - 3.7.6.1 Indonesia

- 3.7.6.2 Thailand
- 3.7.6.3 Philippines
- 3.7.6.4 Vietnam
- 3.7.6.5 Singapore
- 3.7.6.6 Malaysia
- 3.7.6.7 Others in Southeast Asia
- 3.8 Africa & Middle East
 - 3.8.1 South Africa
 - 3.8.2 Egypt
 - 3.8.3 Turkey
 - 3.8.4 Saudi Arabia
 - 3.8.5 Iran
 - 3.8.6 Others in Africa & Middle East

CHAPTER FOUR GLOBAL TOURETTE SYNDROME DRUG BY COMPANIES 2012-2017

- 4.1 Global Tourette Syndrome Drug Sales Volume Market Share by Companies 2012-2017
- 4.2 Global Tourette Syndrome Drug Revenue Share by Companies 2012-2017
- 4.3 Global Top Companies Tourette Syndrome Drug Key Product Model and Market Performance
- 4.4 Global Top Companies Tourette Syndrome Drug Key Target Consumers and Market Performance

CHAPTER FIVE UNITED STATES TOURETTE SYNDROME DRUG BY COMPANIES 2012-2017

- 5.1 United States Tourette Syndrome Drug Sales Volume Market Share by Companies 2012-2017
- 5.2 United States Tourette Syndrome Drug Revenue Share by Companies 2012-2017
- 5.3 United States Top Companies Tourette Syndrome Drug Key Product Model and Market Performance
- 5.4 United States Top Companies Tourette Syndrome Drug Key Target Consumers and Market Performance

CHAPTER SIX GLOBAL TOURETTE SYNDROME DRUG BY CONSUMER 2012-2017

- 6.1 Global Tourette Syndrome Drug Sales Market Share by Consumer 2012-2017
- 6.2 Research Center
- 6.3 Hospital
- 6.4 Clinic
- 6.5 Others
- 6.6 Consuming Habit and Preference

CHAPTER SEVEN GLOBAL TOURETTE SYNDROME DRUG BY CONSUMER 2012-2017

- 7.1 Global Tourette Syndrome Drug Sales Market Share by Consumer 2012-2017
- 7.2 Research Center
- 7.3 Hospital
- 7.4 Clinic
- 7.5 Others
- 7.6 Consuming Habit and Preference

CHAPTER EIGHT TOP COMPANIES PROFILE

- 8.1 Abide Therapeutics Inc
 - 8.1.1 Abide Therapeutics Inc Company Details and Competitors
 - 8.1.2 Abide Therapeutics Inc Key Tourette Syndrome Drug Models and Performance
 - 8.1.3 Abide Therapeutics Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
 - 8.1.4 Abide Therapeutics Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
- 8.2 Catalyst Pharmaceuticals Inc
 - 8.2.1 Catalyst Pharmaceuticals Inc Company Details and Competitors
 - 8.2.2 Catalyst Pharmaceuticals Inc Key Tourette Syndrome Drug Models and Performance
 - 8.2.3 Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
 - 8.2.4 Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
- 8.3 Neurocrine Biosciences Inc
 - 8.3.1 Neurocrine Biosciences Inc Company Details and Competitors
 - 8.3.2 Neurocrine Biosciences Inc Key Tourette Syndrome Drug Models and Performance
 - 8.3.3 Neurocrine Biosciences Inc Tourette Syndrome Drug Business SWOT Analysis

and Forecast

8.3.4 Neurocrine Biosciences Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

8.4 Psyadon Pharmaceuticals Inc

8.4.1 Psyadon Pharmaceuticals Inc Company Details and Competitors

8.4.2 Psyadon Pharmaceuticals Inc Key Tourette Syndrome Drug Models and Performance

8.4.3 Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast

8.4.4 Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

8.5 Reviva Pharmaceuticals Inc

8.5.1 Reviva Pharmaceuticals Inc Company Details and Competitors

8.5.2 Reviva Pharmaceuticals Inc Key Tourette Syndrome Drug Models and Performance

8.5.3 Reviva Pharmaceuticals Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast

8.5.4 Reviva Pharmaceuticals Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

8.6 Synchronuron Inc

8.6.1 Synchronuron Inc Company Details and Competitors

8.6.2 Synchronuron Inc Key Tourette Syndrome Drug Models and Performance

8.6.3 Synchronuron Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast

8.6.4 Synchronuron Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

8.7 Teva Pharmaceutical Industries Ltd

8.7.1 Teva Pharmaceutical Industries Ltd Company Details and Competitors

8.7.2 Teva Pharmaceutical Industries Ltd Key Tourette Syndrome Drug Models and Performance

8.7.3 Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Business SWOT Analysis and Forecast

8.7.4 Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

8.8 Therapix Biosciences Ltd

8.8.1 Therapix Biosciences Ltd Company Details and Competitors

8.8.2 Therapix Biosciences Ltd Key Tourette Syndrome Drug Models and Performance

8.8.3 Therapix Biosciences Ltd Tourette Syndrome Drug Business SWOT Analysis and Forecast

8.8.4 Therapix Biosciences Ltd Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

CHAPTER NINE INDUSTRY CHAIN AND SUPPLY CHAIN

- 9.1 Tourette Syndrome Drug Industry Chain Structure
 - 9.1.1 R&D
 - 9.1.2 Raw Materials (Components)
 - 9.1.3 Manufacturing Plants
 - 9.1.4 Regional Trading (Import Export and Local Sales)
 - 9.1.5 Online Sales Channel
 - 9.1.6 Offline Channel
 - 9.1.7 End Users
- 9.2 Tourette Syndrome Drug Manufacturing
 - 9.2.1 Key Components
 - 9.2.2 Assembly Manufacturing
- 9.3 Consumer Preference
- 9.4 Behavioral Habits
- 9.5 Marketing Environment

CHAPTER TEN GLOBAL TOURETTE SYNDROME DRUG MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

- 10.1 Global Tourette Syndrome Drug Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
- 10.2 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by Regions (2017-2022)
- 10.3 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by Application (2017-2022)
- 10.4 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by -5213 (2017-2022)
- 10.5 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by -115 (2017-2022)
- 10.6 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by etrabenazine ER (2017-2022)
- 10.7 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by pipam Hydrochloride (2017-2022)
- 10.8 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by ers (2017-2022)

CHAPTER ELEVEN UNITED STATES TOURETTE SYNDROME DRUG MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

11.1 United States Tourette Syndrome Drug Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)

11.2 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by Regions (2017-2022)

11.3 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by Application (2017-2022)

11.4 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by -5213 (2017-2022)

11.5 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by -115 (2017-2022)

11.6 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by etrabenazine ER (2017-2022)

11.7 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by pipam Hydrochloride (2017-2022)

11.8 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by ers (2017-2022)

CHAPTER TWELVE DEVELOPMENT TREND AND RESEARCH CONCLUSION

12.1 Development Trend

12.2 Research Conclusion

CHAPTER THIRTEEN METHODOLOGY AND DATA SOURCE

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Table Global Tourette Syndrome Drug Sales Volume (K Pcs), Revenue (Million USD) and Price (USD/Pcs)(2012-2017)

Figure Global Tourette Syndrome Drug Revenue (Million USD) and Growth Rate (2012-2017)

I would like to order

Product name: Global and United States Tourette Syndrome Drug In-Depth Research Report 2017-2022

Product link: <https://marketpublishers.com/r/G2A5569F848EN.html>

Price: US\$ 3,190.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2A5569F848EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970